Showing results filtered by:
50 Results
Peter Rebeiro, Ph.D., K01 sample application
https://www.niaid.nih.gov/sites/default/files/k01-rebeiro-application.pdf
Last Reviewed: March 31, 2025
DMID - Peripheral Blood Mononuclear Cell (PBMC) and Associated Plasma Collection
https://www.niaid.nih.gov/sites/default/files/dmid-lb-sop-00001-pbmc.pdf
Last Reviewed: March 12, 2025
Oye Nana Akuffo, M.B.A., G11 sample application
https://www.niaid.nih.gov/sites/default/files/g11-akuffo-application.pdf
Last Reviewed: March 31, 2025
NIH’s Advisory Committee to the Director (ACD) provides recommendations on program development, resource allocation, NIH administrative regulation, and other aspects of NIH policy.
Published: July 3, 2024
NIAID Biodefense Research Agenda for CDC Category A Agents - 2006 Progress Report
https://www.niaid.nih.gov/sites/default/files/cata_2006.pdf
Last Reviewed: August 6, 2019
Foreign Organization System (FOS) Review (Word)
https://www.niaid.nih.gov/sites/default/files/fosenglish.doc
Last Reviewed: August 6, 2019
Effective writing is an important skill that will benefit a scientist throughout every stage of their career. Postdoctoral fellow Sivarchana Boada, Ph.D., highlights the key components of successful academic and professional writing from January’s three-part skill blitz series.
Published: January 31, 2023
Four Things To Do Before You Apply for an Investigator-Initiated Clinical Trial
Last Reviewed: November 15, 2023
Simmune Simulator Documentation (Meier-Schellersheim)
https://www.niaid.nih.gov/sites/default/files/simsimulatordoc.pdf
Last Reviewed: January 1, 2012
NIAID requires your human subjects research plans to include women, minorities, and participants of all ages unless you can justify their exclusion.
Last Reviewed: January 24, 2022
NIAID DIR 2022 Opportunities Book
https://www.niaid.nih.gov/sites/default/files/2022_DIR_opps_book_QR_sm.pdf
Last Reviewed: November 3, 2022
Food Allergy Summary for Patients, Families, and Caregivers
https://www.niaid.nih.gov/sites/default/files/faguidelinespatient.pdf
Last Reviewed: July 9, 2019
Liu Application
https://www.niaid.nih.gov/sites/default/files/r01ai181321-01-liu-application.pdf
Last Reviewed: November 5, 2024
Infectious-Activities-Teacher.pdf
https://www.niaid.nih.gov/sites/default/files/Infectious-Activities-Teacher.pdf
Last Reviewed: November 8, 2017
Infectious-Activities-Student.pdf
https://www.niaid.nih.gov/sites/default/files/Infectious-Activities-Student.pdf
Last Reviewed: November 8, 2017
vectorworkshop2020
https://www.niaid.nih.gov/sites/default/files/vectorworkshop2020.pdf
Last Reviewed: March 30, 2022
NIH defines a clinical trial as a research study in which one or more human subjects are prospectively assigned to one or more interventions (which may include placebo or other control) to evaluate the effects of those interventions on health-related biomedical or behavioral outcomes.
Published: February 21, 2024
DAIDS SCORE Manual: Introduction to DAIDS Systems
https://www.niaid.nih.gov/sites/default/files/intro-to-daids-systems.pdf
Last Reviewed: January 20, 2021
Molecular Genetics Section (Rosa) Protocols: Transformation of B. burgdorferi Cells
https://www.niaid.nih.gov/sites/default/files/lzp_bbtransformation.pdf
Last Reviewed: August 6, 2019
Molecular Genetics Section (Rosa) Protocols: Competent Cell Preparation
https://www.niaid.nih.gov/sites/default/files/lzp_bbcompetenceprep.pdf
Last Reviewed: August 6, 2019
Design of a Phase 2 Malaria Vaccine Trial Based on a Cohort Study
https://www.niaid.nih.gov/sites/default/files/designphase2malariavaccine.pdf
Last Reviewed: August 6, 2019
NIAID Biodefense Research Agenda for CDC Category A Agents - Progress Report August 2003
https://www.niaid.nih.gov/sites/default/files/category_a_progress_report.pdf
Last Reviewed: August 6, 2019
Candida albicans Murine Vulvovaginal Candidiasis (VVC) Model
https://www.niaid.nih.gov/sites/default/files/sop_candida_albicans_murine_vvc_sop.pdf
Last Reviewed: August 6, 2019
RML BRASS Computational Biology Activity
https://www.niaid.nih.gov/sites/default/files/Computational-Biology-Activity.pdf
Last Reviewed: November 8, 2017
The primary objective of this study is to determine the systemic exposure (AUC24) of letermovir following administration of oral letermovir granules in infants with symptomatic congenital Cytomegalovirus (CMV) disease.